Testing services are crucial for the timely development of viral vector-based medicines since viral vectors are the best strategy for gene therapies. Characterization of the viral vector plays an essential role for orthogonal analytical methods. Through the regulatory prospective which includes product safety, identification, purity, and potency, the characterization is significant. These days, viral vectors are the primary delivery system for a variety of virus-based medications that have been created for various therapies for conditions including cancer, neurology, hematology, ophthalmology, metabolic or muscular disorders and are accepted on the global market. The pharmaceutical industry has a bright future for several developments based on viral-based medicines.
Market Dynamics
The ongoing clinical trials on the viral vectors and plasmid DNA for various treatment is expected to fuel growth of the market in the forecast period. For instance, in October, 2022, ICON plc, a clinical research organization, in collaboration with researchers from Imam Abdulrahman Bin Faisal University, based in Saudi Arabia, announced the initiation of Phase-I clinical trial Study to Evaluate the Safety and Immunogenicity of 2 or 3 dose regimen of investigational Prophylactic pDNA Vaccine Candidate Against COVID-19 in Healthy Adults. The pDNA vaccine candidate is administered intramuscularly (IM) by immunizing healthy adults (18-55 years).
Similarly, in January 2022, GeneOne Life Science, Inc., a biotechnology company, in collaboration with Inovio Pharmaceuticals, a biotechnology company, announced initiation of clinical trial to assess the safety, tolerability, and immunogenicity of GLS-5700. GLS-5700 is a synthetic DNA plasmid vaccine against the Zika virus, which is currently in Phase -1.
Key features of the study:
- This report provides in-depth analysis of the global viral vector and plasmid DNA testing services market, and provides market size (US$ Million) and Compound Annual Growth Rate (CAGR%) for the forecast period (2023–2030), considering 2022 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global viral vector and plasmid DNA testing services market based on the following parameters–company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study are Charles River Laboratories, Inc., WuXi AppTec Co., Ltd., Cobra Biologics and Pharmaceutical Services, Merck KgaA, Lonza, Eurofins Scientific, FinVector Vision Therapies, Advanced Bioscience Laboratories, Inc., Takara Bio Inc., ViruSure GmbH, Genezen Laboratories, Akron Biotech., Catalent, Inc, AcuraBio., CATUG Biotechnology., Creative Biogene and Aldevron
- Insights from this report will allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- Global viral vector and plasmid DNA testing services market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global viral vector and plasmid DNA testing services market
Detailed Segmentation:
- Global Viral Vector and Plasmid DNA Testing Services Market, By Service Type:
- Safety
- Genetic Characterization
- Purity
- Identity
- Potency
- Global Viral Vector and Plasmid DNA Testing Services Market By End User:
- Pharmaceutical and Biotechnology Industries
- Research Organizations
- Global Viral Vector and Plasmid DNA Testing Services Market, By Region:
- North America
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Charles River Laboratories, Inc.
- WuXi AppTec Co., Ltd.
- Cobra Biologics and Pharmaceutical Services
- Merck KgaA
- Lonza
- Eurofins Scientific
- FinVector Vision Therapies
- Advanced Bioscience Laboratories, Inc.
- Takara Bio Inc.
- ViruSure GmbH
- Genezen Laboratories
- Akron Biotech.
- Catalent, Inc
- AcuraBio
- CATUG Biotechnology.
- Creative Biogene.
- Aldevron
